Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

August 8, 2024

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 19 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning, everyone. I'm Andrea, and I'll be serving as your conference operator for today. I'd like to extend a welcome to all of you on this Cronos Group 2024 Second Quarter Earnings Conference Call. This call is being recorded as we speak. At this point, I'll hand things over to Shayne Laidlaw from Investor Relations. Shayne, please go ahead.

Shayne Laidlaw

executive
#2

Thanks, Andrea. I appreciate everyone being here today as we go through Cronos' financial and business results for the second quarter of 2024. With me on the call are Mike Gorenstein, our Chairman, President and CEO, and James Holm, our CFO. This morning Cronos put out a news release with our financial results, and it's been filed on our EDGAR and SEDAR profile. That information, along with the prepared remarks, will also be available on our website in the Investor Relations section. Before handing things over to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Those forward-looking statements rest on management's current expectations and assumptions, which are subject to risks and uncertainties that could make actual results differ materially from what those forward-looking statements project. The factors that could cause actual results to differ materially from expectations are laid out in detail in our earnings materials and our SEC filings, which you can find on our website, and those filings qualify in their entirety any forward-looking statements made on this call. Details on non-GAAP financial measures, including reconciliations to US GAAP, are also in our earnings materials available on our website. Finally, throughout this conference call we will be making statements about market share information, and unless otherwise stated, all market share data comes from Hifyre.

Shayne Laidlaw

executive
#3

We're going to give our prepared remarks at this point, and after that we'll open things up for a question-and-answer session. So with that, I'll hand things over to Mike Gorenstein, who serves as Chairman, President and CEO of Cronos.

Mike Gorenstein

executive
#4

Thanks, Shayne, and good morning to all of you. The Canadian market has been marked by severe cycles of imbalance between supply and demand. During the early period after legalization, supply fell short of demand, and that led a lot of investors and people in the industry to value companies with measures like funded capacity. In effect, this gave higher valuations to firms constructing big cultivation sites, and those firms would then use that to bring in additional capital and construct still more capacity. So a great deal of industry attention went to how large facilities were, rather than to how efficiently they produced or how good the product was. Consequently, overall supply expanded very fast and went well beyond demand. Industry structure and expectations were all built on price assumptions 3 to 4 times the levels seen today, and that produced a market structure featuring high excise tax, high provincial margins and high regulatory fees. But firms whose production facilities were inefficient, having already constructed substantial capacity, needed to secure substantial market share for their business models to succeed, and the push to obtain that share resulted in price compression. A lot of these firms kept raising capital, though on far less favorable terms, and hoped to last long enough to gain from anticipated tailwinds such as appealing international markets opening up or rationalization within the Canadian market.

Mike Gorenstein

executive
#5

A few players chose to skip paying excise taxes as a way to artificially push their production costs down, while certain labs engaged in shopping around to artificially boost how consumers perceived quality through label claims of higher potency. That said, since global macro events had become the priority for policymakers, plenty of producers couldn't hold on long enough to reap the rewards of new markets opening up. During the past year, we've watched the CRA start to intensify collections and enforcement aimed at businesses that aren't remitting excise tax, and regulators have been cracking down on lab shopping, which has driven additional facility closures and bankruptcies. Then earlier this year, thanks to regulatory shifts in Germany and stronger momentum in the UK, international demand at last started to accelerate. As we've noted before, there's a distinction between cannabis inventory that's available and inventory that's available and sellable as quality flower. There's an abundance of the first kind, yet Canada now faces a shortfall of high quality, desirable flower that can actually be sold to consumers. That partly explains why, in June, we announced the expansion of GrowCo to keep fueling our global growth initiatives. GrowCo has demonstrated it's a leading cannabis grower, steadily raising yields and achieving consistent, high THC levels that consumers want. This investment, to be funded through an additional credit facility of roughly $51 million, will back the expansion of GrowCo's state of the art, purpose built cannabis facility so it can meet rising worldwide demand for high quality cannabis flower, opening growth opportunities in the markets Cronos operates in today and enabling future growth into new markets as they open.

Mike Gorenstein

executive
#6

A key part of this deal is that Cronos will consolidate GrowCo and its financial statements in Q3. You've heard me talk extensively before about how strongly GrowCo has performed. Bringing GrowCo into our consolidated results will give investors more information about this part of our business that is underappreciated. Now turning to brand updates. When we launched Spinach, our best selling brand, we deliberately targeted particular consumer segments and product attributes, enhancing the consumer experience. That strategy was essential in making Spinach one of the most recognized and best selling brands in Canada. Our team has brought forward thoughtful innovations across many categories, and I'm extremely proud of what we've achieved on the brand side this quarter. Spinach keeps delivering exceptional results in the flower category in the Canadian market, holding 6.2% market share, led by popular genetics including GMO Cookies, Wedding Cake and Space Cake across a range of size formats. During Q2, we launched Spinach Grindz, a milled flower product conveniently made to be ready to roll or used in various smoking vaporizing devices. Ready to use milled flower products have become more popular in Canada, appealing to consumers who want both value and convenience.

Mike Gorenstein

executive
#7

Spinach Grindz serves this rising demand with premium milled cannabis that reduces the time and effort required. Keeping us at the leading edge of the flower category is our dedication to quality, to innovation, and to investing in genetic breeding. Macro trends indicate that within the next few years, pre-rolls will become the top category in retail sales, which makes succeeding there essential. Pre-rolls are a key focus area for us, and a great deal of work and development is being poured into this segment. As we innovate and iterate in this space, we take particular pride in our recent launches under the Lord Jones brand, which add the Sour Blueberry and Snow Lotus strains to the Ice Water Hash Fusions pre-rolls lineup. What you're seeing from us in pre-rolls today is only the beginning, and we intend to bring new and innovative products to market going forward. In edibles, Spinach held 15.6% market share in Q2. Instrumental to our success in this category has been our focus on developing innovative strategies and products. During Q2, we launched our first variety pack offering, the SOURZ by Spinach Tropical Party Pack, which brings new gummies featuring bolder tropical flavors and the distinctive Spinach S shape.

Mike Gorenstein

executive
#8

These gummies strike an ideal balance between tart and sweet, thanks to Cronos’ proprietary technology for masking flavor, and they come in three new dual flavors: peach passion fruit, pineapple coconut, and strawberry guava. We're eager to roll out these excellent new items under our Spinach brand ahead of the summer season, a time when we know shoppers are looking for convenience and fresh products to sample. Another key addition to our lineup is the new SOURZ by Spinach fully blasted gummies, delivering the same delicious SOURZ by Spinach flavors, but now with 10 milligrams of THC in each piece. This item debuted in select markets earlier this year, yet it only reached Ontario, Canada's largest market, in July. With broader distribution now in place, we anticipate this will generate positive momentum for our edibles portfolio. In June, Health Canada released proposed amendments to the cannabis regulations, which presently cap edibles at 10 milligrams of THC per package. Under the proposed changes, there would be more flexibility to pack multiple packages of edibles together, each holding up to 10 milligrams of THC inside a larger package — an option we would welcome for our best-selling SOURZ edibles. We see this as an excellent step in the right direction toward giving consumers the pack sizes they want, which are popular in other adult-use legalized markets.

Mike Gorenstein

executive
#9

On the vape side, Spinach held the number four spot in the market during the quarter, capturing 6.8% of retail sales in that category. The products driving Spinach's vape results are our best sellers, including Pink Lemonade, Blueberry Dynamite, Strawberry Slurricane and Rocket Icicle. With Lord Jones, our new live resin vape, there's the Gorilla Z strain, offered as a half-gram trial size with the convenience of a very sleek all-in-one device, plus a one-gram stock-up size in a 510-thread cartridge — serving enthusiasts who appreciate live resin's natural flavours as well as adult consumers who are new to the category and want to try this new strain. We keep building out this portfolio to deliver differentiated flavour and cannabinoid combinations to the market in the formats and sizes that consumers want. Now turning to international markets. Our team in Israel continues to deliver very strong results. Tremendous efforts have been made by the Israel team to improve the health of our portfolio, our manufacturing processes and our pricing strategy, which has led to higher volumes of products sold and better pricing for our hero SKUs. During Q2, four new strains were launched by the Israel team: GG4, Kiwi Limez Punch, Pink Sherb and GMO Lite. Our in-house genetic breeding program is what fuels our success in Israel, and it has raised the PEACE NATURALS brand to a leadership position.

Mike Gorenstein

executive
#10

Back in May, we shared news that PEACE NATURALS had reached the UK through Grow Pharma, our distribution partner and a top distributor of prescribed medicinal cannabis products. Serving the UK market — which could expand considerably this year — marks yet another milestone for Cronos as we move into and grow across international markets. Our goal is to make PEACE NATURALS a leading brand in the UK, just as we've achieved in Israel and Germany. We're still concentrated on growing in the markets we've already entered and on bringing more of our borderless products into those markets wherever rules permit. The accomplishments this quarter come from our steadfast dedication to building a portfolio of borderless products backed by strategic infrastructure and global partnerships. Our long-term strategy of putting money into borderless branded innovations designed around specific consumer needs is paying off. We've kept our focus, and our Q2 results demonstrate that. Together, these efforts plus an industry-leading balance sheet position us well to grow in our existing markets and to deliver in whatever new market we choose to enter. With that, I'll hand things over to James, who will walk you through the financials.

James Holm

executive
#11

Thanks, Mike. Good morning, everyone. I'll now walk through our second quarter 2024 results compared with the prior year period. Consolidated net revenue came in at $27.8 million, up 46% from the prior year. Consolidated net revenue on a constant currency basis rose 49% to $28.3 million. The revenue growth was mainly driven by higher sales of cannabis flower and extracts in Canada, higher cannabis flower sales in Israel, and sales in other countries, including Germany and the UK. Gross profit for the second quarter was $6.3 million, equal to a 23% gross margin, which represents a $3.2 million improvement in gross profit and an improvement of roughly 600 basis points in gross margin. That increase was mainly driven by higher sales of cannabis flower and extracts in Canada, higher cannabis flower sales in Israel, and sales in other international markets, partially offset by an adverse price mix in the Canadian cannabis flower category that drove higher excise tax payments as a percentage of revenue. Consolidated adjusted EBITDA for the second quarter was negative $11.1 million, an improvement of $4.9 million from the prior year period. The year-over-year improvement was driven by higher gross profit and lower sales and marketing and general and administrative expenses.

James Holm

executive
#12

You should keep in mind that in the quarter we took a $1.2 million noncash CECL charge, and it sits in our G&A expense line; that charge relates to the extra credit facility tied to GrowCo's expansion and is not adjusted for within the adjusted EBITDA number. That charge is going to reverse when we consolidate in Q3. The tight OpEx discipline we've applied so far has us well down the road toward our 2024 objective of delivering an incremental $5 million to $10 million in savings for Cronos on a standalone basis. Our joint venture GrowCo keeps performing very well, showing strong results that match what we expected. GrowCo told us its preliminary unaudited revenue from third party customers came to roughly $2.7 million in the second quarter. On top of that, the combined credit facility Cronos extended to GrowCo presently carries $74 million outstanding after the $1.2 million principal repayment made in Q2. GrowCo also made an interest payment of $1.4 million during Q2. Mike walked you through the rationale for the deal and the high level numbers, but let me quickly give you some more specifics on the GrowCo transaction. Cronos has extended a second credit facility to GrowCo of approximately $51 million in order to fund expansion of GrowCo's purpose built cannabis facility. With that added investment, the GrowCo Board grows to five members, and Cronos has appointed three of them.

James Holm

executive
#13

We've also signed a new supply agreement giving Cronos the option to buy as much as 70% of total production once the expanded facility comes online. In Q3, 2024, Cronos will consolidate GrowCo's results into its financial statements, and we think that will make clear the considerable strength of GrowCo's performance that has gone underappreciated, along with the benefits it brings to our overall business. We're excited about the growing partnership with our JV partners and look forward to continuing to grow alongside them. Now turning to the balance sheet and cash flow. The company finished the quarter with $848 million in cash and cash equivalents. Cash and cash equivalents declined by $6.9 million from Q1, driven by an $8.8 million outflow in cash from investing activities for advances in loans receivable to fund construction of GrowCo's Phase 2 expansion. Cash flow from operations came in at positive $1.7 million versus a negative $11.8 million in the prior year period. And free cash flow was positive $8 million versus a negative $12.3 million in the prior year period. So that's a significant improvement. Even though our cash balance was down in the quarter, you can see the underlying fundamentals of our operations are showing a significant improvement.

James Holm

executive
#14

Absent that extra funding to grow GrowCo, our balance sheet would have risen by nearly $2 million from one period to the next. Because of the added $51 million put into GrowCo and the facility expansion that came with it, we now expect the net change in cash — which we define as cash plus cash equivalents plus short term investments — to not be positive in 2024. This further investment aimed at expanding GrowCo's purpose built cannabis facility will substantially strengthen our capacity to serve existing markets and to seize additional growth opportunities. Reflecting on the progress achieved so far, I share the confidence in where our business is headed and in how ready we are to enter new markets as they open up. With that, I'd like to turn things back to Mike for a brief comment before we move into Q&A.

Mike Gorenstein

executive
#15

We're headed in the right direction. Revenue is rising, margins are getting better, and costs are coming down — and at the same time we're building our borderless product portfolio, adding new and exciting innovations, and opening up new markets around the world. With that said, I'll open the line for questions.

Operator

operator
#16

Thank you. We'll now move into the question-and-answer portion <<operator_script>>. Joining us first is Yewon Kang of Canaccord Genuity.

Yewon Kang

analyst
#17

Starting with the first item, which concerns the GrowCo investment: I was hoping you could shed some light on the cost-benefit analysis you must have run when deciding whether to put your money into Canada-based GrowCo rather than into production facilities in the international channels you supply, especially since the expansion at GrowCo will be heavily leveraged toward boosting your supplies into those channels?

Mike Gorenstein

executive
#18

As I mentioned at the start of the prepared remarks, we've truly witnessed an enormous change in supply dynamics, where previously there was substantial oversupply. When it comes to high quality flower — which GrowCo has shown it produces consistently — there's genuinely a shortage. And I believe as international markets keep expanding and Canadian supply tightens, that gap is widening from both directions, and we're seeing prices rise. So we think that, not only through what we've achieved in becoming the number one flower brand in Canada but also through the growth we're seeing internationally, this is a really strong way for us to keep fueling growth. Also, from a risk standpoint, with GrowCo already profitable, and looking at the fact that we own 50% and now consolidate, we believe we're in a position to control it. We've watched how they perform for years, and it's a really good way for us to do this. We've been very disciplined and conservative, and we see this as a great risk award overall.

Yewon Kang

analyst
#19

And my second question, as a follow-up, is this. I'd like to ask what your plans now are for the PEACE NATURALS Campus, given that the sale leaseback announced earlier has been terminated. And also, is this idle facility putting any kind of drag on your operations over the past few quarters?

Mike Gorenstein

executive
#20

PEACE NATURALS hasn’t been sitting still, to be clear. That site is in fact where our edibles, a range of derivative goods, and packaging get produced. So it remains our hub. Flower comes in there and gets packaged. Distribution goes out from there. As we keep seeing expansion in Canada and keep adding products, including Lord Jones, we genuinely value having room on a single licensed campus that we can continue to expand into. So we don’t view that as a burden. We believe that, particularly after Phase 2 wraps up, that additional space will be essential for reaching our goals.

Operator

operator
#21

Appreciate it. We'll pause briefly before taking the following question. At this point, I see no additional questions in the queue. Yewon, should you wish to proceed, the floor is yours.

Yewon Kang

analyst
#22

I believe I'm all set. Thanks a lot. Many thanks.

Operator

operator
#23

Thank you. At this point, I see no additional questions. We appreciate everyone joining today's call. That brings the program to a close. You're welcome to disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.